Table 6.

The liposomal NPs based drugs in clinical trials.

Products	Drugs	Status	Applications	Refs
Aroplatin	Cisplatin	Phase II	Colorectal cancer	[216]
Atragen	Tretinoin	Phase II	Leukemia	[217]
Atu027	PKN3 siRNA	Phase II	Solid tumors	[218]
CPX-351	Cytarabine & daunorubicin	Phase III	Myeloid leukemia	[219]
Anti-EGFR immuno-Doxorubicinliposomes	Doxorubicin	Phase I	Solid tumors	[220]
Doxil	Doxorubicin	Approved	Ovarian and breast cancers & Kaposi sarcoma	[221,222]
EndoTAG-1	Paclitaxel	Phase II	Pancreatic & breast cancers	[223]
INX-0125 V	Vinorelbine	Phase I	Solid tumors	[224]
INX-0076	Topotecan	Phase I	Solid tumors	[225]
LipoDox	Doxorubicin	Approved	Ovarian and breast cancers	[226]
LEP-ETU	Paclitaxel	Phase II	Breast, ovarian & lung cancers	[227]
LE-SN38	SN38	Phase II	Colorectal cancer	[228]
Lipoplatin	Cisplatin	Phase III	Breast, pancreatic, neck & head, gastric, and non-squamous non-small cell lung cancers	[229]
Liposomal annamycin	Annamycin	Phase I/II	Lymphocytic leukemia	[230]
Liposomal Grb-2	Grb2-antisenseoligodeoxynucleotide	Phase I	Myeloid leukemia, chronic myelogenous leukemia, & acute lymphoblastic leukemia	[231]
LEM-ETU	Mitoxantrone	Phase I	Breast, stomach, leukemia, breast, stomach, liver, and ovarian cancers	[232]
LiPlaCis	Cisplatin	Phase I	Refractory tumors	[233]
Lipoxal	Oxaliplatin	Phase I	Gastrointestinal cancer	[234]
Myocet	Doxorubicin	Approved	Breast cancer	[235]
Marqibo	Vincristine	Approved	Uveal cancer	[236]
MBP-426	Oxaliplatin	Phase II	Gastroesophageal, gastric & esophageal adeno-carcinomas	[237]
Onivyde	Irinotecan	Approved	Pancreatic cancer	[238]
OSI-211	Lurtotecan	Phase II	Head, ovarian & head and neck cancers	[239]
OSI-7904L	Thymidylate synthaseinhibitor	Phase I/II	Colorectal, head & neck, gastric, and gastroesophageal cancers	[240]
Stimuvax	BLP25 Tecemotide	Phase III	Multiple myeloma developed encephalitis	[241]
SPI-077	Cisplatin	Phase II	Ovarian and head and neck cancers	[242]
ThermoDox	Doxorubicin	Phase III	Non-resectable hepatocellular cancer	[243]